ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,567.19
      1.06%
      US Tech 100
      19,828.00
      0.95%
      Dow Jones
      39,375.87
      0.17%
      Brent Oil
      86.115
      -0.45%
      Bitcoin
      55,158.20
      -1.23%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Celgene Corporation (CELG)

      7. Celgene Corporation (CELG) News

      CELG

      Celgene (CELG)

      Celgene Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CELG
      DateTimeSourceHeadlineSymbolCompany
      12/21/20175:29PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CELGCelgene Corporation
      12/21/20174:30PMBusiness WireCelgene & LYSARC Provide Update on Phase III ‘RELEVANCE’ Study of REVLIMID® in Combination with Rituximab (R2) for the T...NASDAQ:CELGCelgene Corporation
      12/20/20174:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      12/20/20174:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      12/20/20174:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      12/20/20174:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      12/14/20174:02PMEdgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CELGCelgene Corporation
      12/11/20177:00AMBusiness WireJuno Therapeutics & Celgene Corp. Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refrac...NASDAQ:CELGCelgene Corporation
      12/10/201710:30AMBusiness WireCelgene Corp. & bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell T...NASDAQ:CELGCelgene Corporation
      12/07/201711:45AMBusiness WireLong-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE®...NASDAQ:CELGCelgene Corporation
      12/06/20174:47PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      12/05/20177:30AMBusiness WireCelgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained CountriesNASDAQ:CELGCelgene Corporation
      11/28/20178:00AMGlobeNewswire Inc.Analysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals —...NASDAQ:CELGCelgene Corporation
      11/21/20178:00AMBusiness WireResults from 282 Abstracts Including Celgene Therapies & Pipeline Compounds to Be Presented at the American Society of Hemato...NASDAQ:CELGCelgene Corporation
      11/21/20177:30AMBusiness WireCelgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in DecemberNASDAQ:CELGCelgene Corporation
      11/17/20172:30AMBusiness WireRésultats d'efficacité et de tolérance du second essai de Phase III (RADIANCE™ partie B) d'Ozanimod, administré par voi...NASDAQ:CELGCelgene Corporation
      11/16/20178:30AMBusiness WireCelgene Corp. & bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation f...NASDAQ:CELGCelgene Corporation
      11/09/20175:20PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CELGCelgene Corporation
      11/07/20173:00AMBusiness WireErgebnisse zur Wirksamkeit und Sicherheit aus RADIANCE™ (Teil B), der zweiten Phase-III-Studie zu oralem Ozanimod im Vergle...NASDAQ:CELGCelgene Corporation
      11/07/20173:00AMBusiness WireErgebnisse zur Wirksamkeit und Sicherheit aus SUNBEAM™, der ersten Phase-III-Studie zu oralem Ozanimod im Vergleich zu eine...NASDAQ:CELGCelgene Corporation
      11/03/201710:07AMBusiness WireRésultats d'efficacité et de tolérance du premier essai de phase III d’ozanimod, administré par voie orale (SUNBEAM™)...NASDAQ:CELGCelgene Corporation
      11/01/20175:18PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:CELGCelgene Corporation
      11/01/20174:13PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      11/01/20173:47PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CELGCelgene Corporation
      11/01/20177:30AMBusiness WireCelgene Prices $3 Billion of Senior Unsecured NotesNASDAQ:CELGCelgene Corporation
      10/31/20175:22PMEdgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:CELGCelgene Corporation
      10/31/20174:13PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      10/31/20174:13PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      10/31/20174:13PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
      10/31/20174:12PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
       Showing the most relevant articles for your search:NASDAQ:CELG